Literature DB >> 24868326

NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.

Igor Bakulin1, Victor Pasechnikov1, Anna Varlamicheva1, Irina Sannikova1.   

Abstract

A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-α and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of PIs administered in clinical settings.

Entities:  

Keywords:  Adverse event; Antiviral treatment; Hepatitis C virus; PEGylated interferon-α; Protease inhibitor; Response-guided therapy; Ribavirin

Year:  2014        PMID： 24868326      PMCID： PMC4033290          DOI： 10.4254/wjh.v6.i5.326

Source DB:  PubMed          Journal:  World J Hepatol


  27 in total

Review 1.  The era of direct-acting antivirals has begun: the beginning of the end for HCV?

Authors:  Marie-Louise Vachon; Douglas T Dieterich
Journal:  Semin Liver Dis       Date:  2011-12-21       Impact factor: 6.115

Review 2.  Replication of hepatitis C virus.

Authors:  Darius Moradpour; François Penin; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2007-05-08       Impact factor: 60.633

3.  Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).

Authors:  Ingrid Imhof; Peter Simmonds
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

4.  Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.

Authors:  Michael W Fried; Maria Buti; Gregory J Dore; Robert Flisiak; Peter Ferenci; Ira Jacobson; Patrick Marcellin; Michael Manns; Igor Nikitin; Fred Poordad; Morris Sherman; Stefan Zeuzem; Jane Scott; Leen Gilles; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt; Maria Beumont-Mauviel
Journal:  Hepatology       Date:  2013-10-11       Impact factor: 17.425

Review 5.  Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes.

Authors:  Stéphane Chevaliez; Jean-Michel Pawlotsky
Journal:  Best Pract Res Clin Gastroenterol       Date:  2008       Impact factor: 3.043

6.  Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

Authors:  Mark S Sulkowski; Tarik Asselah; Jacob Lalezari; Peter Ferenci; Hugo Fainboim; Barbara Leggett; Fernando Bessone; Stefan Mauss; Jeong Heo; Yakov Datsenko; Jerry O Stern; George Kukolj; Joseph Scherer; Gerhard Nehmiz; Gerhard G Steinmann; Wulf O Böcher
Journal:  Hepatology       Date:  2013-06       Impact factor: 17.425

7.  Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.

Authors:  Patrick Marcellin; Curtis Cooper; Luis Balart; Dominique Larrey; Terry Box; Eric Yoshida; Eric Lawitz; Peter Buggisch; Peter Ferenci; Martin Weltman; Emily Labriola-Tompkins; Sophie Le Pogam; Isabel Nájera; Denise Thomas; Gregory Hooper; Nancy S Shulman; Ying Zhang; Mercidita T Navarro; Chin Yin Lim; Michael Brunda; Norah A Terrault; Ellen S Yetzer
Journal:  Gastroenterology       Date:  2013-06-26       Impact factor: 22.682

8.  Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

Authors:  Mark S Sulkowski; Marc Bourlière; Jean-Pierre Bronowicki; Tarik Asselah; Jean-Michel Pawlotsky; Stephen D Shafran; Stanislas Pol; Stefan Mauss; Dominique Larrey; Yakov Datsenko; Jerry O Stern; George Kukolj; Joseph Scherer; Gerhard Nehmiz; Gerhard G Steinmann; Wulf O Böcher
Journal:  Hepatology       Date:  2013-06       Impact factor: 17.425

9.  Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.

Authors:  Yoshiyuki Suzuki; Kenji Ikeda; Fumitaka Suzuki; Joji Toyota; Yoshiyasu Karino; Kazuaki Chayama; Yoshiiku Kawakami; Hiroki Ishikawa; Hideaki Watanabe; Wenhua Hu; Timothy Eley; Fiona McPhee; Eric Hughes; Hiromitsu Kumada
Journal:  J Hepatol       Date:  2012-11-23       Impact factor: 25.083

10.  Exploratory study of oral combination antiviral therapy for hepatitis C.

Authors:  Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245
View more
  2 in total

1.  HIV and HCV Medications in End-Stage Renal Disease.

Authors:  Keiko I Greenberg; Mark A Perazella; Mohamed G Atta
Journal:  Semin Dial       Date:  2015-04-06       Impact factor: 3.455

Review 2.  Hepatitis C virus: Virology, diagnosis and treatment.

Authors:  Hui-Chun Li; Shih-Yen Lo
Journal:  World J Hepatol       Date:  2015-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.